What are the components of the classic thrombotic thrombocytopenic purpura (TTP) pentad?

TTP Pentad Components

The classic TTP pentad consists of five components: thrombocytopenia, microangiopathic hemolytic anemia, neurological abnormalities, renal dysfunction, and fever. 1, 2, 3

Historical Context and Clinical Reality

The pentad was traditionally used to characterize thrombotic thrombocytopenic purpura, but this complete presentation is only observed in approximately 40% of cases 1. Modern diagnosis does not require all five features to be present, as waiting for the full pentad can dangerously delay treatment 4, 5.

The Five Components

1. Thrombocytopenia

• Severe reduction in platelet count is a hallmark feature 1, 2, 3
• Can present with platelet counts as low as 6,000/cubic millimeter 6

2. Microangiopathic Hemolytic Anemia (MAHA)

• Non-immune hemolysis with presence of schistocytes on peripheral blood smear 4, 1, 2
• Critical pitfall: Schistocytes may be absent on initial peripheral smear and only appear later in the disease course 6
• The absence of abundant schistocytes does not exclude TMA due to low test sensitivity 4

3. Neurological Abnormalities

• Most frequent manifestation, occurring in 75.3% of patients 7
• Can range from headache and confusion to severe mental status changes requiring intubation 2, 6
• Neurological symptoms are common according to the CDC 4

4. Renal Dysfunction

• Renal impairment is part of the classic triad defining TMA (microangiopathic hemolysis, thrombocytopenia, and organ involvement—typically renal) 4
• Can present as rapidly progressive renal dysfunction 1

5. Fever

• Completes the pentad but is not universally present 1, 2, 3

Modern Diagnostic Approach

Do not wait for the complete pentad before initiating treatment. The presence of thrombocytopenia and microangiopathic hemolytic anemia alone should trigger immediate TMA evaluation and consideration of TTP 4, 2. Critical first-line tests include ADAMTS13 activity level and inhibitor titer, complete blood count with platelet count, lactate dehydrogenase, direct antiglobulin test, peripheral blood smear review, creatinine, and urinalysis 4.

For suspected TTP with ADAMTS13 activity <10%, immediately initiate therapeutic plasma exchange and administer methylprednisolone 1g IV daily for 3 days—do not delay plasma exchange while awaiting ADAMTS13 results, as mortality increases with delayed treatment 4, 5.